Skip to content
DataLookout
Menu

NCT07903493

Phase Ia Study of MST-931 in Healthy Adult Subjects

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Study sites: 0 to 1
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percentage of subjects with drug related adverse events (AEs)
Timeframe: Through study completion, up to 113 days

Secondary (4)

PK parameters for MST-931: Area Under Curve (AUC)
PK parameters for MST-931: Maximum Observed Concentration (Cmax)
PK parameters for MST-931: Time of maximum observed concentration (Tmax)
PK parameters for MST-931: Elimination Half-life (t1/2)

Arms and interventions

MST-931 dose level 1 treatment CohortExperimental

MST-931 dose level 1

MST-931 dose level 2 treatment CohortExperimental

MST-931 dose level 2

MST-931 dose level 3 treatment CohortExperimental

MST-931 dose level 3

MST-931 dose level 4 treatment CohortExperimental

MST-931 dose level 4

Matching placebo for each dose groupPlacebo comparator

Matching placebo

Biologicals: MST-931, MST-931 Placebo

Sites

1 site in 1 country

  • Q-Pharm Pty LtdHerston, Queensland, Australia